Rua Bioscience Results of 2021 Annual Shareholders’ Meeting

Rua Bioscience (NZX: RUA) advises that all resolutions put to its hybrid Annual Shareholders' Meeting (held online and in Gisborne yesterday) were passed by Shareholders. Those resolutions being: - That the Board be authorised to fix the auditor's remuneration. - That Martin Smith be re-elected as a director of Rua. The results of the voting poll are in the attached document. Ends For more information, please visit www.ruabio.com or contact: Media Kerry Donovan Communications Manager +64 (21) 128 7689 kerry.donovan@ruabio.com Investors Hamish White Chief Financial Officer +64 (21) 050 5795 Hamish.white@ruabio.com About Rua Bioscience Rua Bioscience is a New Zealand pharmaceutical company aiming to produce cannabinoid derived medicines for both export and local markets. Rua has been an early mover in the sector and was the first private company in New Zealand to receive a licence to cultivate Cannabis for research purposes. Founded in 2017 in Ruatorea as a subsidiary of charitable company Hikurangi Enterprises Limited, Rua is underpinned by its mission to heal the people and heal the land. It is committed to New Zealand's Te Tairawhiti (East Coast) region and its local community. The Company has completed facilities for cultivation and manufacturing and is currently going through the GMP certification process. www.ruabio.com End CA:00381321 For:RUA Type:MEETING Time:2021-10-20 15:53:43